Results 51 to 60 of about 55,569 (166)
Editorial for the Special Issue: Clostridium difficile
Microorganisms, 2021 Clostridium difficile (reclassified as Clostridioides difficile [...]
Łukasz M. Grześkowiak
doaj +1 more source
Advanced Science, EarlyView.This study is pioneering in constructing the shortest known synthetic pathway for L‐theanine production from xylose within E coli. Through comprehensive metabolic engineering strategies, our engineered strain achieved the highest reported L‐theanine titer from xylose, with a titer of 95.42 g/L, and a yield of 0.55 g/g.
Haolin Han +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Atypical colitis (presenting reverse gradient colitis, backwash ileitis or rectal sparing) is associated with primary sclerosing cholangitis–ulcerative colitis (PSC). Oral vancomycin has been used to manage paediatric atypical colitis with/without confirmed PSC. Different preparations had shown different efficacy.
Laura Räisänen +4 more
wiley +1 more source
An atypical case of infection by Clostridium difficile
Microbiologia Medica, 2010 Clostridium difficile is a Gram-positive human pathogenic bacterium and nosocomial pathogen; it is the causative agent diarrhoea, colitis and pseudo-membranous colitis associated with antibiotic therapy.
Maria Cristina Neri +5 more
doaj +1 more source
Disarming Clostridium difficile
Chemistry & Biology, 2010 In this issue, Puriet al. (2010) present inhibitors that prevent the autocatalytic activation of the clostridial toxin TcdB in vivo. Their approach is likely to provide guidance for the development of novel drugs targeting virulence factors and thereby rendering bacterial pathogens innocuous.
Gersch, Malte, Sieber, Stephan A.
openaire +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale +5 more
wiley +1 more source
In vitro activities of MCB3681 and 8 comparators against Clostridium difficile isolates with known ribotypes and diverse geographical spread [PDF]
, 2017 Treatments for Clostridium difficile infection remain limited, despite the introduction of fidaxomicin, and development of new agents is necessary.
Freeman, J +3 more
core +1 more source
Role of Microbiota and Innate Immunity in Recurrent Clostridium difficile Infection
Journal of Immunology Research, 2014 Recurrent Clostridium difficile infection represents a burdensome clinical issue whose epidemiology is increasing worldwide. The pathogenesis is not yet completely known.
Stefano Bibbò +5 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse +3 more
wiley +1 more source
Journal of Medical Case Reports, 2018 Background Recurrent Clostridium difficile infection is a growing problem among children due to both the increasing survival of medically fragile children with complicated chronic medical conditions resulting in prolonged antibiotic exposure and ...
D. E. Dow, P. C. Seed
doaj +1 more source